These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16937304)

  • 21. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
    Hudes G; Einhorn L; Ross E; Balsham A; Loehrer P; Ramsey H; Sprandio J; Entmacher M; Dugan W; Ansari R; Monaco F; Hanna M; Roth B
    J Clin Oncol; 1999 Oct; 17(10):3160-6. PubMed ID: 10506613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
    J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
    Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.
    Berry WR; Hathorn JW; Dakhil SR; Loesch DM; Jackson DV; Gregurich MA; Newcomb-Fernandez JK; Asmar L
    Clin Prostate Cancer; 2004 Sep; 3(2):104-11. PubMed ID: 15479494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer.
    Albrecht W; Van Poppel H; Horenblas S; Mickisch G; Horwich A; Serretta V; Casetta G; Maréchal JM; Jones WG; Kalman S; Sylvester R
    Br J Cancer; 2004 Jan; 90(1):100-5. PubMed ID: 14710214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
    Vaughn DJ; Brown AW; Harker WG; Huh S; Miller L; Rinaldi D; Kabbinavar F
    Cancer; 2004 Feb; 100(4):746-50. PubMed ID: 14770430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Optimal treatment for elderly high-risk prostate cancer patients].
    Soga N; Sugimura Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):387-92. PubMed ID: 17353629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Sumiyoshi Y; Hashine K; Nakatsuzi H; Yamashita Y; Karashima T
    Int J Urol; 2000 Jul; 7(7):243-7. PubMed ID: 10910225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R; Nordle O; Josefsson K
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine plus uracil/tegafur therapy for prostate cancer.
    Ono Y; Ohshima S; Takahashi Y; Kuriyama M; Kawada Y; Shimizu H
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):120-4. PubMed ID: 10442379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical efficacy of leuprolide acetate and combined treatment with estramustine for advanced prostate cancer].
    Saito S; Nakashima J; Nakajima Y; Ikeuchi K; Shibayama T; Nagakura K; Naide Y; Hayakawa M; Ogawa Y; Hata M; Nakazono M; Hasegawa S; Oda T; Kimura S; Nakamura S; Matsunaga J; Fujioka T; Tanoguchi H; Aoki S; Yamamoto Y; Izawa A; Kimura S; Suzuki K; Tazaki H; Murai M;
    Nihon Hinyokika Gakkai Zasshi; 2001 Nov; 92(7):682-93. PubMed ID: 11766367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
    Kikuno N; Urakami S; Nakamura S; Hiraoka T; Hyuga T; Arichi N; Wake K; Sumura M; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
    Eur Urol; 2007 May; 51(5):1252-8. PubMed ID: 17208356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.